Breaking News, Collaborations & Alliances

Bespak Expands Manufacturing Capacity to Support Chiesi CMI Program

The two companies share a long-term vision of delivering lower carbon inhaled therapies through CMIs at scale.

Author Image

By: Patrick Lavery

Content Marketing Editor

Bespak is increasing pressurized metered dose inhaler (pMDI) manufacturing capacity to support Chiesi Group’s Carbon Minimal Inhaler (CMI) program. The added capacity at the Holmes Chapel, UK site is part of an expansion of Chiesi and Bespak’s long-standing partnership. Chiesi is an international research-focused biopharmaceutical company; Bespak is a specialist inhalation CDMO concentrating on pulmonary and nasal drug delivery. CMI Goals Shared by Chiesi, Bespak The two companies say t...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters